Welcome to our dedicated page for Fortress Biotech news (Ticker: FBIO), a resource for investors and traders seeking the latest updates and insights on Fortress Biotech stock.
Fortress Biotech, Inc. operates a biopharmaceutical business built around acquiring and advancing pharmaceutical and biotechnology assets. Company updates commonly cover product revenue, equity holdings, dividend and royalty income, FDA decisions, subsidiary transactions and clinical or regulatory progress across its portfolio.
Recurring news also includes Journey Medical dermatology products, Cyprium Therapeutics and ZYCUBO® for Menkes disease, priority review voucher monetization and corporate financial results. Fortress reports material developments involving approved prescription products, portfolio-company ownership, royalties, capital resources and business-development activity.
Journey Medical (Nasdaq: DERM) expanded payer access for Emrosi™, increasing commercial lives reached from approximately 100 million to over 150 million as of April 1, 2026.
Approximately 85% of U.S. commercial lives now have access after contracting with a third major GPO. The company expects expanded access to support prescription growth and improved brand profitability as formulary adoption progresses through 2026.
Fortress Biotech (Nasdaq: FBIO) reported 2025 results and material portfolio events. Key items: FDA approval of ZYCUBO® for Menkes disease, sale of a Rare Pediatric Disease PRV for $205 million by subsidiary Cyprium, and the May 2025 Checkpoint acquisition by Sun Pharma that generated ~$355 million upfront consideration to the seller group and a long‑term royalty stream.
Consolidated 2025 net revenue was $63.3M, R&D was $11.9M, SG&A was $96.4M, and net loss attributable to common stockholders was $1.9M (‑$0.07 per share).
Fortress Biotech (Nasdaq: FBIO) and majority-owned subsidiary Cyprium Therapeutics closed the sale of Cyprium’s Rare Pediatric Disease Priority Review Voucher for gross proceeds of $205 million on March 30, 2026. Fortress expects to receive over $100 million of the proceeds, improving liquidity for business development.
The PRV was issued after FDA approval of ZYCUBO on January 12, 2026. Cyprium remains eligible for tiered royalties on ZYCUBO sales and up to approximately $128 million in aggregate sales milestones from Sentynl. Cyprium must pay 20% of PRV proceeds to the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Journey Medical (Nasdaq: DERM) reported full-year 2025 results and corporate highlights on March 25, 2026. Total revenues were $61.9 million, up 10% from $56.1 million in 2024, driven by the commercial launch of Emrosi™ (net revenues $14.7 million; ~53,000 prescriptions).
Gross margin improved to 66.2%, Adjusted EBITDA was $2.9 million, cash was approximately $24.1 million, and working capital was $29.4 million. Net loss narrowed to $11.4 million (−$0.47/share).
Journey Medical (Nasdaq: DERM) will release its year-end 2025 financial results after market close on March 25, 2026.
The company will host a conference call and live audio webcast the same day at 4:30 p.m. ET; registration is available online and the replay will remain available about 30 days.
Fortress Biotech (Nasdaq: FBIO) subsidiary Cyprium Therapeutics entered a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $205 million in gross proceeds upon closing. The PRV was issued following FDA approval of ZYCUBO on January 12, 2026 and was transferred to Cyprium.
Cyprium remains eligible for tiered royalties on ZYCUBO net sales and up to $129 million in aggregate milestones from Sentynl; 20% of PRV sale proceeds are payable to the Eunice Kennedy Shriver NICHD. The deal is subject to customary closing conditions, including the HSR waiting period.
Fortress Biotech (Nasdaq: FBIO) and majority-owned Cyprium announced FDA approval of ZYCUBO® (copper histidinate) on January 13, 2026, as the first and only U.S. treatment for Menkes disease.
Key commercial terms: a Rare Pediatric Disease Priority Review Voucher will transfer to Cyprium, and Cyprium is eligible for tiered royalties plus up to $129 million in development and sales milestones from Sentynl. Clinical data showed a nearly 80% reduction in risk of death for early-treated patients and median overall survival of 177.1 months vs 17.6 months for the external control.
Fortress Biotech (Nasdaq: FBIO) and majority-owned Cyprium Therapeutics announced FDA acceptance of the CUTX-101 NDA resubmission as a Class 1 resubmission with a new PDUFA target action date of January 14, 2026. Sentynl Therapeutics resubmitted the NDA on November 14, 2025 after a September 30, 2025 complete response letter that cited observations about the manufacturing site's cGMP compliance but did not identify safety or efficacy deficiencies. Clinical topline data reportedly show significant improvement in overall survival for Menkes disease patients treated early. Under the Sentynl transaction, Sentynl will transfer a Rare Pediatric Disease PRV to Cyprium if approval is issued, and Cyprium is eligible for royalties plus up to $129 million in development and sales milestones.
Journey Medical (Nasdaq: DERM) reported publication (Dec 10, 2025) of Phase 1 results for Emrosi (DFD-29) in the Journal of Drugs in Dermatology.
The multicenter, randomized, double-blind study enrolled 60 healthy adults (2:1 DFD-29:placebo), dosing once daily for 16 weeks. The trial met all three primary microbiological endpoints: no significant change in skin, GI, or vaginal microbiota; no detectable minocycline resistance; and no emergence of opportunistic organisms. No significant safety issues were reported. Emrosi (40 mg minocycline modified-release: 10 mg immediate + 30 mg extended) is FDA-approved in the U.S. for inflammatory rosacea lesions in adults.
Fortress Biotech (NASDAQ: FBIO) reported Q3 2025 total net revenue of $17.6M, a 20.5% increase versus Q3 2024, driven largely by Journey Medical dermatology sales. Journey Medical net product revenue was $17.0M in the quarter vs. $14.6M a year earlier. Fortress reported consolidated net income of $3.7M ($0.13 basic, $0.11 diluted) versus a loss of $(15.0)M in Q3 2024. Consolidated cash totaled $86.2M as of Sept 30, 2025, up $28.9M year-to-date. Corporate updates include Sun Pharma's acquisition of Checkpoint (Fortress received ~$28M upfront plus potential CVR and a 2.5% royalty), dotinurad entering two Phase 3 trials, and an FDA CRL for CUTX-101 citing manufacturing (cGMP) observations with a planned resubmission.